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Available online xxxxObjective.Women exposed to diethylstilbestrol in utero (DES) have an increased risk of clear cell adenocar-
cinoma (CCA) of the vagina and cervix, while their risk of non-CCA invasive cervical cancer is still unclear.
Methods.We studied the risk of pre-cancerous (CIN) lesions and non-CCA invasive cervical cancer in a pro-
spective cohort of 12,182womenwith self-reportedDES exposure followed from 2000 till 2008.We took screen-
ing behavior carefully into account. Incidence was obtained through linkage with the Netherlands Nationwide
Pathology database (PALGA). General population data were also derived from PALGA.
Results. The incidence of CIN1 was increased (Standardized Incidence Ratio (SIR) = 2.8, 95% Conﬁdence In-
terval (CI)= 2.3 to 3.4), but no increased riskwas observed for CIN2+ (CIN2, CIN3 or invasive cancer) compared
to the screened general population (SIR = 1.1, 95% CI = 0.95 to1.4). Women with DES-related malformations
had increased risks of both CIN1 and CIN2+ (SIR = 4.1, 95%CI = 3.0 to 5.3 and SIR = 1.5, 95%CI = 1.1 to 2.0,
respectively). For CIN2+, this risk increase was largely restricted to women with malformations who were
more intensively screened.
Conclusions.An increased risk of CIN1 among DES daughterswas observed, especially inwomenwith DES-re-
latedmalformations, probablymainly due to screening. The risk of CIN2+ (including cancer) was not increased.
However, among DES daughters with DES-related malformations a true small risk increase for non-CCA cervical
cancer cannot be excluded.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In the late 1940s to the early 1970s several millions of pregnant
womenworldwide receivedDiethylstilbestrol (DES) in order to prevent
miscarriages and other pregnancy complications [1–4]. Next to high risk
of clear cell adenocarcinoma of the vagina and cervix (CCA), the well-y, Netherlands Cancer Institute,
. This is an open access article under
sk of cervical intra-epithelial
yno.2016.11.048established adverse health effects in the female offspring (DES daugh-
ters) include several reproductive tract abnormalities, among which
are the presence of glandular tissue (adenosis) and metaplastic squa-
mous epithelium in the vagina and ectocervix. It has been speculated
that these epithelial changes might increase the risk of cancer, not
only adenocarcinoma, but also squamous cell cancer, and precancerous
lesions [5–8]. A two-fold risk of cervical dysplasia (CIN2+) was ob-
served in the National Cancer Institute's DES Combined Cohort Fol-
low-up Study (NCI DES study), with a 74% increased risk among DES
daughters who had vaginal epithelial changes [7,8]. For invasivethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ous report of our Dutch DES cohort a (non-statistically signiﬁcant) de-
creased risk of invasive squamous cell cervical cancer was found [10].
In this reportwe examined the risk of cervical intra-epithelial lesions
(CIN) and cervical cancer in a large cohort of Dutch DES-daughters,
compared to the screened general population. A unique feature of this
study is that all outcomes and reference data were obtained from the
Netherlands nationwide pathology database (PALGA), which enabled
us to account for screening behavior.
2. Patients and methods
The DES-net project is a nationwide retrospective cohort study with
prospective follow-up among DES daughters in the Netherlands. DES
daughters were identiﬁed through the registry of the Netherlands DES
Center that was established in 1992 in order to deal with future health
claims. Documented DES exposure at time of registration was not re-
quired. In the period March 2000–December 2004 DES daughters
were sent a 16-page self-administered questionnaire about risk factors
for hormone-related cancers and medical history (response 63%, sup-
plementary Fig. 1). In addition to the questionnaire, women granted
permission to abstract data from their medical records by means of a
written informed consent. Furthermore, women provided us, if avail-
able, with a copy of themedical ﬁle of their mothers inwhichDES expo-
sure in utero was conﬁrmed.
3. Assessment of outcome and screening history
Detailed information on CIN, invasive cervical cancer and screening
history was retrieved from PALGA [11]. PALGA is a nationwide database
of excerpts of all histopathology and cytopathology reports made since
1989. The PALGA Surveillance Committee granted us permission to link
all study subjects with PALGA (both responders and non-responders to
the questionnaire, but refusers (6%) excluded) under strict privacy pro-
cedures. The study was approved by the Institutional Review Board of
the Netherlands Cancer Institute.
All CINs and cancer were coded according to the systemized nomen-
clature of medicine (SNOMED). For each woman the ﬁrst occurrence of
the highest grade of CIN was used in the analysis (supplementary Table
1). CIN1 was deﬁned as mild dysplasia, CIN2 as moderate dysplasia,
CIN3 as severe dysplasia or carcinoma in situ and cervical cancer as in-
vasive cervical squamous cell carcinoma and non-CCA adenocarcinoma.
CIN2+was deﬁned as a combination of CIN2, CIN3 and invasive cancer.
For each woman the number of episodes, as a proxy for the number of
screening rounds, was calculated. By deﬁnition, a screening episode
started with a primary smear, if necessary followed by secondary
smears in case of an abnormal smear or a smear of inadequate quality.
An episode ended when follow-up was complete according to the
Dutch guidelines (i.e. the dates of the third consecutive negative smears
after a primary smear with high grade squamous cell intra-epithelial le-
sion (HSIL) smear, the second consecutive negative smears after a pri-
mary smear with low grade squamous cell intra-epithelial lesion
(LSIL), the one consecutive adequate smear after a primary smear of in-
adequate qualitywithin 6months, or at the date 4 years after the prima-
ry smear when no (adequate) follow-up smears were done. Thus, by
deﬁnition, post-diagnostic follow-up smears were attributed to the
same episode as the diagnosed lesion.
4. Covariates
Questionnaire data on DES-related reproductive tract abnormalities
(including adenosis, squamous cell metaplasia, transverse vaginal
ridges, cockscomb, cervical collars, hoods, pseudo-polyps, hypoplastic
cervix, uterine cavum malformations and tubal malformations) were
veriﬁed by medical ﬁle. The term vaginal/cervical epithelial changes
(VCEC) is used to refer to adenosis or squamous cell metaplasia ofPlease cite this article as: J. Verloop, et al., Risk of cervical intra-epithelial
Oncol (2016), http://dx.doi.org/10.1016/j.ygyno.2016.11.048both the vagina and the ecto-cervix (enlarged ectropion). Other covari-
ates (educational level, indication for maternal DES usage, age at ﬁrst
gynaecological DES examination, and number of smears and
colposcopies during ﬁve years preceding the questionnaire) were
based on self-report. Vital statuswas obtained by linkagewith theNeth-
erlands Ofﬁce of Death Registry (CBG) and updated till October 2007.5. Veriﬁcation of DES exposure
Documented DES exposure was available for a minority of subjects.
Mothers' medical records were hard to trace as archives of hospitals
and general practitioners had been destroyed. For a subgroup of partic-
ipants (n= 115) we veriﬁed self-reported DES exposure with medical
records in four hospitals where all records had been kept [10]. For 76%
of the women DES exposure was conﬁrmed, in 3% a medicine different
from DES was recorded and in 21% no DES was mentioned in the hospi-
tal medical ﬁle, while prescription by general practitioner could not be
excluded. Because the agreement between self-report and veriﬁed
DES-exposure was acceptable, we included all women in the analyses,
irrespective of whether DES exposure was medically veriﬁed.6. Statistical analysis
Follow-up started on January 1st 2000, at age 29 years, whichever
was last. We excluded women younger than age 29 because the Dutch
general population screening program is restricted to women aged
30–60 years, and women are invited in the year they become
30 years. Follow-up ended at 30th November 2008, the date of ﬁrst oc-
currence of intra-epithelial cervical neoplasia (CIN) or cervical cancer,
death, date of uterus extirpation/cervix amputation, date of the 65th an-
niversary, whichever came ﬁrst. After exclusion of ineligible women
(n = 287, supplementary Fig. 1), 11,895 women (100,287 person-
years) were left for analyses.
Standardized Incidence Ratios (SIRs) were calculated by compar-
ing the number of observed cases with CIN and invasive cervical can-
cer in our study with age-, sex- and calendar period–speciﬁc
numbers from PALGA [12,13]. The number of women at risk in the
general population was obtained from Statistics Netherlands
(www.cbs.nl) and adjusted for women without an uterus (from the
Dutch Hospital Discharge database (LMR), based on 5-year age cate-
gories (30–64)). To calculate the total number of screened women at
risk in the general population we additionally applied 5-year cover-
age rates per ﬁve year age category from the year 2005 [14] (supple-
mentary, Table 2). 95% conﬁdence intervals (CI) were calculated
assuming a Poisson distribution [15].
Because it is generally known that ﬁrst screens have higher detect-
ing rates than following tests, we excluded prevalent lesions, detected
during the ﬁrst screening episode, both in the general population as
the study population. In order to achieve this for the latter population,
analyses were restricted to participants who reported to have had a
smear during the ﬁve years preceding the questionnaire. Furthermore,
we calculated SIRs for women stratiﬁed according to the number of ep-
isodes, the presence of DES-relatedmalformations and attained age. Ad-
ditionally, we examined which type of examination (biopsy or
cytology) andwhich outcomedirectly preceded the histological diagno-
sis of CIN.
We used the Kaplan-Meier method to compare the cumulative
incidence of CIN lesions among subgroups of women. Furthermore,
Cox regression analysis was performed to calculate hazard ratios
(HR) in order to quantify the effect of different covariates on the
risk of CIN within the exposed cohort, with adjustment for the
other covariates. Both in the Kaplan-Meier and the Cox regression
model, age was used as the time metric. All analyses were conducted
using STATA release 11 SE.neoplasia and invasive cancer of the cervix in DES daughters, Gynecol
Table 1
Characteristics of 11,895 DES daughters and the subgroup of cases diagnosedwith cervical
intra-epithelial neoplasia (all grades) and cervical cancer during follow-up, 2000–2008.
Characteristic
All women
(N = 11,894)
CIN (all grades) and
cervical cancera
(N = 392)
N (%) N (%)
Year of birth
≤ 1955 1446 (12) 27 (7)
1956–1960 2496 (21) 66 (17)
1961–1965 2926 (25) 108 (27)
1966–1970 3405 (29) 147 (37)
N 1970 1621 (14) 44 (11)
Age at end of follow up
30–40 y 3.124 (28) 117 (30)
40–49 y 6088 (51) 216 (55)
50+ y 2682 (23) 59 (15)
Year of registration
1992 11,009 (93) 357 (91)
1993–1999 601 (5) 13 (3)
2000–2005 284 (2) 22 (6)
Questionnaire completed
Yes 7478 (63) 263 (67)
No 4416 (37) 129 (33)
Number of screening episodes
during follow-upb
0 episodes 2074 (17) 0 (0)
1–2 episodes 4779 (40) 128 (33)
3–5 episodes 3612 (30) 189 (48)
N 5 episodes 1429 (12) 75 (18)
Number of cervical/vaginal smears
Cervical smears
0 2091 (18) 3 (1)
1–2 4400 (37) 27 (7)
3–5 3496 (29) 112 (28)
N 5 1907 (16) 250 (64)
Vaginal smears
0 8866 (75) 217 (55)
1 1148 (10) 43 (11)
2–5 1511(13) 98 (25)
N 5 369 (3) 34 (9)
Number of biopsies
Cervical biopsies
0 11,023 (93) 0 (0)
1 584 (5) 151 (39)
N 1 287 (2) 241 (61)
Vaginal biopsies
0 11,793 (99) 372 (95)
≥1 101 (1) 20 (5)
Treatment
No treatment 11,025 (93) 192 (49)
Biopsy 517 (4) 8 (2)
Lis excision, conisation 263 (2) 178 (46)
Resection, extirpation 25 (0) 14 (4)
Women with questionnaire only
All
women
N = 7478
CIN (all grades) and
cervical cancer
N = 263
DES conﬁrmation
Medical ﬁle mother 871 (12) 36 (14)
DES-related reproductive tract abnormalities
(VCEC and structural abnormalities)
1630 (22) 87 (33)
History of frequent vaginal screening (before
age 50) or frequent cervical screening before
age 30)
1953 (26) 82 (31)
No information available 3024 (40) 58 (22)
Year of ﬁrst gynaecological examinationc
No DES-related gynaecological examination 1396 (19) 36 (14)
b 1992 4638 (62) 178 (68)
1992–1999 891 (12) 33 (12)
N 2000 23 (0) 2 (1)
Missing 530 (7) 14 (5)
Age at ﬁrst gynaecological examinationc
No DES-related gynaecological examination 1396 (19) 36 (14)
b 20 2425 (32) 111 (42)
20–29 2402 (32) 84 (32)
30+ 725 (10) 18 (7)
Table 1 (continued)
Women with questionnaire only
All
women
N = 7478
CIN (all grades) and
cervical cancer
N = 263
Missing 530 (7) 14 (5)
Medical indication DES use mother
Both threatened and habitual abortion 1289 (17) 50 (19)
Threatened abortion only 1879 (25) 58 (22)
Habitual abortion only 3790 (51) 137 (52)
Other reason/unknown 520 (7) 18 (7)
Highest educational level
Primary school 939 (13) 31 (12)
Secondary school 3551 (47) 123 (47)
College or university 2835 (38) 100 (38)
Unknown or missing 153 (2) 9 (3)
Number of Pap smears during 5 years preceding
questionnaire
No smears 431 (6) 4 (2)
1–2 2646 (35) 67 (25)
N 3 4030 (54) 177 (67)
Unknown or missing 371 (5) 15 (6)
Number of colposcopies during 5 years
preceding questionnaire
No colposcopies 1829 (24) 48 (18)
1–2 2236 (30) 91 (35)
N 3 1168 (16) 75 (29)
Unknown or missing 2245 (30) 49 (18)
Medically veriﬁed DES-related malformationsd
Not reported 5321 (71) 154 (59)
Adenosis, squamous neoplasia (VCEC) 1347 (18) 79 (30)
Structural anomalies 555 (7) 22 (8)
Not speciﬁed 205 (3) 7 (3)
Missing 50 (1) 1 (0)
a CIN = cervical intra-epithelial lesion; VCEC = vaginal/cervical epithelial changes.
b Screening episodes deﬁned as primary smear and, if necessary, followed by secondary
smears in case of an abnormal smear of a smear of inadequate quality.
c Gynaecological examination (any of these): palpation, colposcopy, cervical smears
and/or vaginal smears.
d 813 women with both VCEC and structural abnormalities were categorized as VCEC.
VCEC included cervical and vaginal adenosis and squamous cell metaplasia. Structural ab-
normalities included transverse vaginal ridges, cockscomb, cervical collars, hoods, pseudo-
polyps, hypoplastic cervix, uterine cavum malformations and tubal malformations.
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Among the 11,894 women in our analytic cohort, 392 women (3%)
had a histologically conﬁrmed CIN lesion or cervical cancer detected
during follow-up (Table 1). Fifteen women had two lesions (same or
different grade) at different time points during follow-up (results not
shown). The number of screening episodes was remarkably high
among cases; 66% had more than two episodes during follow-up com-
pared to 42% in the total DES-exposed cohort. In addition, and also high-
ly correlated to the number of episodes, women with CIN or invasive
cancer had undergone a higher number of smears and biopsies com-
pared to the total cohort (N5 cervical smears: 64% and 16%, respective-
ly). Seventy-four percent of the cases reported to have had their ﬁrst
gynaecological examination before age 30 compared to 64% of the
total cohort. The majority of women had had a Pap smear in the ﬁve
years preceding the questionnaire, with the number of colposcopies
being considerably higher among cases (64% versus 46% in the total
group). Documented DES exposure was available for 871 women
among whom were 36 cases. The higher proportion of cases with DES
documentation was probably caused by their search for these records
after diagnosis of CIN/invasive cancer or DES-related malformations.
Cases more often had DES-related malformations compared to the en-
tire cohort, of which VCEC occurred most frequently (32% and 20% for
cases and entire cohort, respectively).
Table 2 describes the risk of CIN and cervical cancer among DES
daughters compared to the screened female population. For CIN1 le-
sions an increased risk was observed (SIR = 2.8, 95% CI = 2.3 to 3.4).
SIR estimates for CIN2 and CIN3were above one but not statistically sig-
niﬁcant and for invasive cervical cancer a decreased risk (SIR = 0.29,neoplasia and invasive cancer of the cervix in DES daughters, Gynecol
Table 2
Standardized incidence ratios of cervical intraepithelial lesions and cervical cancer for DES daughters with questionnaire data, by DES-relatedmalformations and number of screening ep-
isodes, follow-up period 2000–2008.
Screened women
CIN1a CIN2a CIN3a
First episode excl. PYb Obs Exp SIR 95%CI Obs Exp SIR 95%CI Obs Exp SIR 95%CI
Overall 50,987 118 42 2.8 2.3–3.4 49 37 1.3 0.97–1.7 75 65.8 1.1 0.90–1.4
Screening rounds
1–2 episodes 20,416 25 16.4 1.5 0.99–2.3 16 14.6 1.1 0.63–1.8 23 25.5 0.9 0.57–1.4
N 2 episodes 30,570 93 25.2 3.7 3.0–4.5 33 22.8 1.5 0.99–2.0 52 40.3 1.3 0.96–1.7
DES-related malformationsc
No malformations 35,339 65 28.5 2.3 1.8–2.9 33 25.5 1.3 0.89–1.8 40 44.9 0.9 0.64–1.2
1–2 episodes 16,190 9 12.9 0.7 0.32–1.3 13 11.4 1.1 0.61–1.9 18 20 0.9 0.53–1.4
N 2 episodes 19,149 56 51.6 3.6 2.7–4.6 20 14.1 1.4 0.87–2.2 22 24.9 0.88 0.55–1.3
Malformations 15,647 53 13.0 4.1 3.0–5.3 16 11.8 1.4 0.77–2.2 35 20.9 1.7 1.2–2.3
1–2 episodes 4227 16 3.5 4.6 2.6–7.5 3 3.1 0.96 0.20–2.8 5 5.5 0.91 0.30–2.1
N 2 episodes 11,421 37 9.6 3.9 2.7–5.3 13 8.7 1.5 0.80–2.6 30 15.4 1.9 1.3–2.8
VCEC 9993 38 8.3 4.6 3.2–6.3 10 7.6 1.3 0.63–2.4 27 13.4 2.0 1.3–2.9
1–2 episodes 2598 9 2.1 4.2 1.9–8.0 2 1.9 1 0.13–3.8 5 3.4 1.5 0.48–3.5
N 2 episodes 7395 29 6.2 4.7 3.1–6.7 8 5.7 1.4 0.61–2.8 22 10.1 2.2 1.4–3.3
Anatomical and unspeciﬁed malformations 5655 15 4.7 3.2 1.8–5.3 6 4.2 1.4 0.52–3.1 8 7.5 1.1 0.46–2.1
1–2 episodes 1629 7 1.3 5.2 2.1–10.8 1 1.2 0.8 0.02–4.6 0 2.1
N 2 episodes 4026 8 3.4 2.4 1.0–4.7 5 3 1.6 0.5–3.8 8 5.4 1.5 0.6–2.9
Screened women
Cervical cancera CIN2+a
First episode excl. PYb Obs Exp SIR 95%CI Obs Exp SIR 95%CI
Overall 50,987 2 7 0.29 0.04–1.0 126 110 1.1 0.95–1.4
Screening rounds
1–2 episodes 20,416 1 2.8 0.36 0.01–2.0 40 42.8 0.93 0.67–1.3
N 2 episodes 30,570 1 4.2 0.24 0.006–1.3 86 67.3 1.3 1.0–1.6
DES-related malformationsc
No malformations 35,339 1 4.8 0.21 0.01–1.2 74 75.2 0.98 0.77–1.2
1–2 episodes 16,190 1 2.2 0.45 0.01–2.5 32 33.6 0.95 0.65–1.3
N 2 episodes 19,149 0 2.6 42 41.6 1 0.73–1.4
Malformations 15,647 1 2.2 0.5 0.01–2.6 52 34.9 1.5 1.1–2.0
1–2 episodes 4227 0 0.6 8 9.2 0.87 0.38–1.7
N 2 episodes 11,421 1 1.6 0.63 0.02–3.5 44 25.7 1.7 1.2–2.3
VCEC 9993 1 1.4 0.72 0.02–4.0 38 22.4 1.7 1.2–2.3
1–2 episodes 2598 0 0.4 7 5.6 1.2 0.50–2.6
N 2 episodes 7395 1 1 0.97 0.03–5.4 31 16.8 1.8 1.3–2.6
Anatomical and unspeciﬁed malformations 5655 0 0.8 14 12.5 1.1 0.61–1.9
1–2 episodes 1629 0 0.2 1 3.6 0.28 0.01–1.6
N 2 episodes 4026 0 0.6 13 9 1.5 0.77–2.5
a CIN: cervical intra-epithelial neoplasia. CIN1 (grade 1): Mild dyskaryosis CIN2 (grade 2): moderate dyskaryosis CIN3 (grade 3): severe dyskaryosis/dysplasia or carcinoma in situ.
CIN2+ is including cancer. Cancer morphology: 1 squamous cell carcinoma, 1 adenocarcinoma.
b PY= person years, Obs= observed, Exp= expected, SIR= Standardized incidence ratio, deﬁned as observed number of cancers compared to the expected number of cancers in the
general population with the same age; 95%CI = 95% conﬁdence interval based on a Poisson distribution.
c Deﬁnition (medically veriﬁed) DES-related malformations: Anatomical malformations: transverse vaginal ridges, cockscomb, cervical collars, hoods, pseudo-polyps, hypoplastic
cervix, uterine cavummalformations and tubal malformations. VCEC: cervical and vaginal adenosis and squamous cell metaplasia. Malformations were self-reported in the questionnaire
(at start of the follow-up) and validated by medical ﬁle.
Table 3
Risk of cervical dysplasia and cancer among screened DES daughters by attained age (ex-
clusion of lesions diagnosed at ﬁrst screening episode).
All PYa
Attained age b40d Attained age 40+d
p
differencec
24,345 26,642
Type of
lesionb
Obsa Exp SIR 95%CI Obs Exp SIR 95%CI
CIN1 65 20.4 3.2 2.4–4.1 53 21.2 2.5 1.9–3.3 0.19
CIN2 27 20.1 1.3 0.88–2.0 22 17.2 1.3 0.80–1.9 0.86
CIN3 48 38 1.3 0.93–1.7 27 27.8 0.97 0.64–1.4 0.27
Cervical
cancer
1 3 0.33 0.01–1.8 1 4 0.25 0.01–1.4 0.85
CIN2+ 76 61.1 1.2 0.98–1.6 50 49 1 0.76–1.4 0.28
a PY = person years, Obs = observed, Exp = expected, SIR = Standardized incidence
ratio, deﬁned as observed number of cancers compared to the expected number of cancers
in the general population Cancer morphology: 1 squamous cell carcinoma, 1
adenocarcinoma.
b CIN: cervical intra-epithelial neoplasia. CIN1 (grade 1): Mild dyskaryosis CIN2 (grade
2): moderate dyskaryosis CIN3 (grade 3): severe dyskaryosis/dysplasia or carcinoma in
situ. CIN2+ is including cancer. Cancer morphology: 1 squamous cell carcinoma, 1
adenocarcinoma.
c p difference based on Poisson distribution.
d attained age= age at diagnosis of (ﬁrst, maximum) CIN or age at end follow-up (30th
November 2008).
4 J. Verloop et al. / Gynecologic Oncology xxx (2016) xxx–xxx
Please cite this article as: J. Verloop, et al., Risk of cervical intra-epithelial
Oncol (2016), http://dx.doi.org/10.1016/j.ygyno.2016.11.04895% CI = 0.04 to 1.0) was observed. No increased risk for CIN2+was
found (SIR = 1.1, 95% CI = 0.95 to 1.4). Among women with more
than two screening episodes the risks for both CIN1 and CIN2+
were increased (SIR = 3.7, 95% CI = 3.0 to 4.5 and SIR = 1.3, 95%
CI = 1.0 to 1.6, respectively). DES daughters with one to two epi-
sodes (suggestive of following the 5-yearly general population cervi-
cal screening program) had a less pronounced increased risk of CIN1
(SIR = 1.5, 95% CI = 0.99 to 2.3) and the risk of CIN2+ (SIR = 0.93,
95% CI = 0.67 to 1.3) was no longer increased. Among women with
DES-related malformations the risks of CIN1 and CIN2+ were both
elevated compared to the screened general population, with the
risk increases being most pronounced in the VCEC-group (SIR =
4.6, 95% CI = 3.2 to 6.3 and SIR = 1.7, 95% CI = 1.2 to 2.3 for CIN1
and CIN2+, respectively).
The SIRs did not vary according to attained age, but numbers were
small (Table 3). The risk of CIN1 seemed to be slightly higher among
women younger than 40 than at older ages. To study whether the
high number of histologically veriﬁed CIN1 lesions might be the result
of more invasive diagnosticmethodswe examinedwhich type of exam-
ination and outcome preceded the histological diagnosis (Table 4). Half
of the CIN1 lesions were preceded by a smear with borderline or mild
dyskaryosis which was comparable to general population ﬁgures. Aneoplasia and invasive cancer of the cervix in DES daughters, Gynecol
Table 4
Preceding primary test results in relation to histologically conﬁrmed lesions for 393 DES daughters with CIN lesions and (invasive) cervical cancer.
Result of primary test
Histologically conﬁrmed lesiona
Total N(%)Cancer N(%) CIN3 N(%) CIN2 N(%) CIN1 N(%)
Smearsb
Cancer 0 (0%) 6 (5%) 0 (0%) 0 (0%) 6 (2%)
Carcinoma in situ 1 (20%) 11 (9%) 0 (0%) 2 (1%) 14 (4%)
Severe dyskaryosis (HSIL) 1 (20%) 34 (26%) 9 (10%) 4 (2%) 48 (12%)
Moderate dyskaryosis (HSIL) 0 (0%) 35 (27%) 23 (26%) 13 (8%) 71 (18%)
Mild dyskaryosis (LSIL) 0 (0%) 22 (17%) 27 (30%) 45 (27%) 94 (24%)
Borderline dyskaryosis/ASCUS 0 (0%) 16 (12%) 18 (20%) 44 (26%) 78 (20%)
Biopsies
Cancer 3 (60%) 0 (0%) 0 (0%) 0 (0%) 3 (1%)
CIN3 0 (0%) 3 (2%) 0 (0%) 0 (0%) 3 (1%)
CIN2 0 (0%) 2 (2%) 11 (12%) 0 (0%) 13 (3%)
CIN1 0 (0%) 0 (0%) 1 (1%) 61 (36%) 62 (16%)
Total 5 129 89 169 392
a CIN: cervical intra-epithelial neoplasia. CIN1 (grade 1): Mild dyskaryosis CIN2 (grade 2): moderate dyskaryosis CIN3 (grade 3): severe dyskaryosis/dysplasia or carcinoma in situ.
Cancer morphology: 2 squamous cell carcinoma, 2 adenocarcinoma 1 adenosquamous cell carcinoma.
b HSIL = High grade squamous intraepithelial lesion, LSIL = Lowgrade squameuze intra-epitheliale lesion, ASCUS = atypical squamous cells of undetermined signiﬁcance.
5J. Verloop et al. / Gynecologic Oncology xxx (2016) xxx–xxxremarkable ﬁnding was the high proportion of cases with CIN1 that
were preceded by biopsies without a preceding smear (36%), which
might be indicative of biopsies directed by abnormal colposcopic ﬁnd-
ings or because of complaints.
The number of episodes was an important predictor for detecting a
CIN1 lesion, but not as much for a CIN2+ lesion (HRadj = 1.99, 95%
CI = 1.24 to 3.11 and HR = 1.22, 95% CI = 0.82 to 1.81,
respectively)(Table 5, Fig. 1a). Rather, the risk of CIN2+ lesions was
slightly increased for women with a history of VCEC or DES-related an-
atomical abnormalities, though not statistically signiﬁcantly so
(HRadj = 1.47, 95% CI = 0.96 to 2.27 and HR = 1.52, 95% CI = 0.91 to
2.53, respectively, see also Fig. 1b).Table 5
Univariate and multivariate Hazard Ratios for different risk factors for CIN and cervical cancer.
Screened women, exclusion of the ﬁrst episode
CIN1a
Univariate
HR 95%CI
Episodesb
1–2 episodes 1.00 Reference
N 2 episodes 2.43 1.56–3.79
DES-related malformationsc
No malformations 1.00 Reference
VCEC 1.90 1.26–2.84
Structural abnormalities 1.22 0.69–2.16
Not speciﬁed 1.66 0.66–4.13
Primary school 1.00 Reference
Secondary school 0.84 0.48–1.47
College or university 0.79 0.44–1.41
Unknown or missing 1.97 0.66–5.90
Age ﬁrst gynaecological DES-examinatione
No examination 1.00 Reference
b 20 2.83 1.22–6.54
20–29 2.64 1.16–5.97
30+ 2.02 0.78–5.40
Missing 1.39 0.44–4.42
Number of colposcopies (5 year preceding questionnaire)d
No colposcopies 1.00 Reference
1–2 1.16 0.69–1.96
N 3 2.09 1.23–3.54
Unknown or missing 0.65 0.35–1.20
HR = Hazard ratio.
a CIN: cervical intra-epithelial neoplasia. CIN1 (grade 1), CIN2+: including CIN2, CIN3 and c
b Screening episodes deﬁned as primary smear and, if necessary, followed by secondary sm
c Deﬁnition DES-related malformations: Anatomical malformations: transverse vaginal ridge
malformations and tubalmalformations. VCEC: cervical and vaginal adenosis and squamous cel
up) and validated by medical ﬁle.
d Based on self-report.
e Multivariate analysis: adjusted for all other risk factors.
Please cite this article as: J. Verloop, et al., Risk of cervical intra-epithelial
Oncol (2016), http://dx.doi.org/10.1016/j.ygyno.2016.11.0488. Discussion
In this studywe comprehensively evaluated the risk of CIN and non-
CCA cervical cancer amongDES daughters with complete follow-up and
based on medically veriﬁed outcome data. Whereas for low-grade CIN
lesions (CIN1) a statistically signiﬁcantly increased risk was observed
in DES daughters compared to the screened general population, the
overall risk of CIN2+ (CIN2/3 or invasive cancer) was not increased.
However, in women with DES-related malformations increased risks
of both CIN1 and CIN2+ were found, with the increased risks being
most pronounced in women with VCEC who had been intensively
screened.CIN2 plusa
Multivariatee Univariate Multivariateb
HR 95%CI HR 95%CI HR 95%CI
1.00 Reference 1.00 Reference 1.00 Reference
1.99 1.24–3.11 1.31 0.90–1.9 1.22 0.82–1.81
1.00 Reference 1.00 Reference 1.00 Reference
1.38 0.90–2.12 1.68 1.13–2.49 1.47 0.96–2.27
1.05 0.59–1.86 1.49 0.90–2.46 1.52 0.91–2.53
1.24 0.50–3.13 0.58 0.14–2.38 0.56 0.14–2.32
1.00 Reference 1.00 Reference 1.00 Reference
0.81 0.46–1.42 1.18 0.64–2.2 1.19 0.64–2.21
0.75 0.42–1.34 1.26 0.67–2.37 1.24 0.66–2.33
1.94 0.65–5.83 1.24 0.28–5.54 1.18 0.26–5.29
1.00 Reference 1.00 Reference 1.00 Reference
1.71 0.71–4.11 0.76 0.45–1.31 0.44 0.23–0.80
1.63 0.69–3.83 0.60 0.34–1.03 0.34 0.19–0.63
1.29 0.47–3.51 0.45 0.18–1.13 0.26 0.10–0.69
0.98 0.30–3.18 0.56 0.24–1.33 0.36 0.15–0.88
1.00 Reference 1.00 Reference 1.00 Reference
0.95 0.55–1.61 1.36 0.82–2.25 1.53 0.90–2.60
1.46 0.84–2.54 1.92 1.13–3.27 2.13 1.19–3.81
0.64 0.35–1.19 0.71 0.39–1.30 0.74 0.40–1.36
ervical cancer (CCA excluded).
ears in case of an abnormal smear of a smear of inadequate quality.
s, cockscomb, cervical collars, hoods, pseudo-polyps, hypoplastic cervix, uterine cavum
lmetaplasia. Malformationswere self-reported in the questionnaire (at start of the follow-
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Fig. 1. A. Kaplan Meier estimates for CIN1 lesions by number of episodes. B. Kaplan Meier estimates for CIN1 lesions by DES-related malformation. C. Kaplan Meier estimates for CIN2+
lesions by number of episodes. D. Kaplan Meier estimates for CIN2+ lesions by DES-related malformation.
6 J. Verloop et al. / Gynecologic Oncology xxx (2016) xxx–xxxTo our knowledge, the risk of histologically conﬁrmed CIN1 among
DES daughters has not been studied before. In 1984, Robboy et al. did
examine the risk ofmild dysplasia amongDES daughters, butwith inclu-
sion of lesions that were veriﬁed by cytology only [6]. Histological de-
tection of CIN lesions, especially with regard to mild lesions, is shown
to vary by differences in diagnostic criteria, follow-up recommenda-
tions and referral rates [16]. Also, a high frequency of screening might
lead to overdiagnosis of CIN lesions that have a high chance of regres-
sion [17–19]. Furthermore, the detection of CIN1 lesions in DES daugh-
ters might suffer from histological misclassiﬁcation due to the common
presence of VCEC and a wider transformation zone [20]. Thus, the ob-
served increased risk of CIN1 among DES daughters seems mainly at-
tributable to intensive screening (cytological screening next to
screening by regular coloposcopic examinations) as part of the DES
screening protocol [21].
Another important ﬁnding of our study is that we found no over-
all increased risk for CIN2+. This seems in contrast with the NCI DES
study [5–8] including 4062 DES-exposed women 1837 unexposed
controls, for which a two-fold risk of high grade CIN was reported
(HR= 1.98, 95% CI= 1.33 to 2.94) [5–8]. However, a consistent ﬁnd-
ing was the increased risk of CIN2+ for womenwith VCEC compared
to non-exposed women (HR= 2.40, 95% CI = 1.60 to 3.61 and SIR =
1.7, 95% CI = 1.2 to 2.3, in the NCI-study of 2011 (supplementary
Table 5) [7] and our study, respectively). Interestingly, when we
stratiﬁed on screening frequency, the increased risk of CIN2+ in
women with VCEC appeared to be restricted to the most intensively
screened group. More intensive screening in DES daughters with
VCEC (through smears and colposcopic surveillance) may causePlease cite this article as: J. Verloop, et al., Risk of cervical intra-epithelial
Oncol (2016), http://dx.doi.org/10.1016/j.ygyno.2016.11.048overdiagnosis of CIN2+, not only by detection of lesions that
would have regressed spontaneously, but also by possible misinter-
pretation of VCEC as severe or moderate dyskaryosis. Whether the
observed increased risk of CIN2+ is real or an artifact of screening
could not be detangled. Most probably, both are true and a real
small increased risk of CIN2+ is somewhat enlarged by intensive
screening.
There are two reasons why our SIR estimates may be biased to zero,
and the estimates of the NCI DES study biased away from the null; the
age range included and the data sources used. We excluded women
younger than 29, because our national screening program starts at the
year a woman turns 30 years. If the SIR at young ages is higher than
later on, our SIR estimate is biased to zero if applied to the entire age
range. However, the internal reference group of unexposed controls
younger than age 30 in the NCI-DES studymay have been screened nei-
ther, resulting in bias away from the null. Another important difference
between the two studies was the self-reported data on outcome and
screening (NCI-DES study) or exposure (DES-net study). We had a rela-
tively small number of women with veriﬁed DES-exposure, while the
exposure of NCI-DES daughters was 100% validated. We estimated
that at least 76% of our cohort members was DES-exposed [10]. As a re-
sult, our overall risks might be somewhat diluted by inclusion of non-
exposed women. However, misclassiﬁcation of exposure is expected
to be minimal in our analysis of women with DES-related
malformations (with an attributable risk of 90% [3,22,23]). Women
with self-reported DES-related malformations comprised 36% of the
current analytic cohort. In the NCI-DES cohort the proportion was
slightly higher (45% = 1864/3795) [7] which may reﬂect still someneoplasia and invasive cancer of the cervix in DES daughters, Gynecol
7J. Verloop et al. / Gynecologic Oncology xxx (2016) xxx–xxxmisclassiﬁcation in our cohort, but may also be the result of differences
in cumulative DES dosage or timing of DES exposure [24].
In our study complete screening information from PALGAwas avail-
able. We only missed the colposcopies that were not accompanied by
smears. In the NCI-DES cohort health outcomes and screening history
were based on self-report. Underreporting or unawareness of abnormal
ﬁndings by the unexposed group might have biased the results away
from zero. Bias in the same direction might result from incomplete ad-
justment for the screening history [5]. Whereas the use of PALGA data
enabled us to adequately control for screening, we could not adjust for
confounding. Known risk factors for cervical cancer, like human papillo-
ma virus (HPV) infection, age at ﬁrst intercourse, number of partners
and smoking, may have resulted in confounding [19,25]It is well
established that HPV infection is the necessary cause of invasive non-
CCA cervical cancer [26]. However, HPV infection alonemay not be suf-
ﬁcient and other cofactors, like high parity, smoking and long-term oral
contraceptive use, may be necessary for the transition from HPV infec-
tion to HSIL/invasive cancer [18]. It is uncertain whether HPV infection
plays a role in DES-related tumors like CCA [27]. It has been suggested
that the cervical tissue in women with VCECmight be more susceptible
to carcinogenic factors like an HPV-infection, which might explain the
increased risk estimates of CIN for women with VCEC [5,20]. Another
explanation might be that DES daughters have an altered immune sys-
tem, which renders them more vulnerable to persistent HPV-infection
[28,29].
In conclusion, the increased risk of CIN1 among DES daughters, which
was most pronounced in women with DES-related malformations,
seemed mainly due to intensive screening. The risk of CIN2+ was not
increased, suggesting that DES daughters in general do not have an
increased risk of cervical cancer (non-CCA) compared to the general
population. Among the more frequently screened DES daughters with
DES-related malformations overdiagnosis by screening and a potentially
small increased risk of CIN2+ could not be disentangled. Our ﬁndings
underscore the importance of being cautious with respect to invasive
diagnostic procedures or treatment since overdiagnosis seem to occur in
a group of women which is already strongly medicalized.
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